# Immupharma PLC Update on LupuzorT Pivotal Phase III Study

- Link: https://www.directorstalkinterviews.com/immupharma-plc-update-lupuzort-pivotal-phase-iii-study/412735810
- Published: 2017-09-21T07:05:37+01:00
- Author: Giles Arbor

**ImmuPharma PLC** (LON:IMM), the specialist drug discovery and development company,
has today provided the following update of its pivotal 52-week, randomised, double-
blinded, Phase III clinical trial of Lupuzor™, its lead programme for the potential
breakthrough compound for Lupus, the life threatening auto-immune disease.

· Study summary as at 15th September 2017

· 200 patients successfully recruited and randomised (dosed)

o all patients in the study have passed the 6 months stage

o 52 patients (26%) have completed the full 12 months of the study

· Continued robust safety record which remains consistent with Lupuzor™’s product
profile as shown in its previous Phase IIb study

· Top line results remain on track to be reported in Q1 2018

> **Commenting on the trial update, Tim McCarthy, Chairman of ImmuPharma Plc said:**“
> We are pleased to provide a further update of our pivotal Phase III study of Lupuzor
> ™ in Lupus. All patients in the study have now passed the six months stage, with
> 52 patients (26%) having completed the full 12 months. We will now see an accelerated
> number of patients completing the full 12 months of the trial over the next couple
> of months. Importantly, with Lupuzor™ being administered to greater numbers of
> patients over a longer period of time, we are delighted to be observing the continuation
> of our robust safety profile.
> “With an urgent need for a new treatment for Lupus which is safe and effective,
> we are observing an ever increasing focus from the market, the scientific community
> and patient groups on Lupuzor™ as we get closer to completing this pivotal Phase
> III study. We are looking forward with confidence to the outcome of the trial 
> and to reporting, on track, the top line results in Q1 2018.”

Share on: